PremiumRatingsCautious Outlook on DBV Technologies: Sell Rating Amid Commercialization and Market Risks DBV Technologies reinstated with a Sell at Goldman Sachs DBV Technologies price target raised to $21 from $15 at Citizens JMP PremiumPre-Earnings0QAJ Upcoming Earnings Report: What to Expect? Biotech Alert: Searches spiking for these stocks today DBV sinks after disclosing ‘substantial doubt’ of going concern PremiumThe FlyDBV Technologies announces three-year results from EPITOPE trial DBV Technologies announces FDA alignment on Viaskin Peanut patch program pathway DBV jumps 52% to $4.99 after aligning with FDA on approval pathway 
